Better understanding the development/maintenance of GLP‐1 neurons, combinatorial therapy involving GLP‐1 designer agonists, as well as the acute versus chronic effects of GLP‐1 on the brain will undoubtedly be growing areas of study to better understand the therapeutic benefits of this system in metabolic disease. This evidence concerns the gene GLP1R and metabolic disease.